LUCD$1.44
Chart
Performance
Key Stats
AI LUCD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldLucid Diagnostics Inc. (LUCD) presents a mixed investment profile. While operating in a high-potential market (esophageal cancer prevention), its current financial performance is challenging, with negative earnings and significant operating expenses relative to revenue. Technical indicators show some recent positive momentum on shorter timeframes, but the overall trend and valuation remain cautionary. Consider for highly speculative portfolios or those with a high risk tolerance.
Thematic
Lucid Diagnostics operates within the medical diagnostics sector, specifically targeting early detection of esophageal precancer and cancer through its EsoGuard Esophageal DNA Test and EsoCheck device. The growing awareness of GERD-related risks and advancements in diagnostic technology provide a favorable thematic backdrop. However, the company's current stage of commercialization and reliance on a single core product are key considerations.
Fundamental
Lucid Diagnostics exhibits significant financial challenges. High operating expenses, negative gross profit, and substantial net losses are evident. While cash reserves have been bolstered by financing activities, the company is burning through cash rapidly, leading to a negative free cash flow. The valuation metrics, particularly Price-to-Sales (P/S), are extremely high given the current revenue and negative earnings.
Technical
Short-term technical indicators show some mixed signals. Moving averages on very short timeframes (1m, 5m) suggest potential buying pressure, but longer-term daily and hourly charts indicate a bearish trend with prices below key moving averages. Oscillators are mostly neutral or leaning towards bearish. The stock has experienced recent volatility.
| Factor | Score |
|---|---|
| Medical Diagnostics Innovation | 75 |
| Healthcare Spending Trends | 70 |
| Biotech/Medtech Regulatory Environment | 60 |
| Company-Specific Commercialization Risk | 55 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 70 |
| Balance Sheet Health | 25 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 45 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improving EPS Trend
Recent quarterly EPS estimates have shown a positive trend, with the latest reported EPS (-0.18) exceeding the estimate (-0.19). This indicates potential for positive surprises in future earnings.
Positive Short-Term Performance
The stock has shown positive performance over the last month (+10.59%) and year-to-date (+39.8%), suggesting recent investor interest and positive momentum.
Bearish Points (8)
Consistent EPS Misses
The company has consistently missed earnings estimates in recent quarters (e.g., Q2 2025: -229.64% surprise, Q4 2024: -13.64% surprise), indicating challenges in meeting financial expectations.
Negative Profitability and Margins
The company has negative EPS (EPS TTM: -1.17) and negative net income across all reported periods (e.g., 2024 Net Income: -45.529M). Net margins are significantly negative, reflecting substantial operating losses.
Calendar
August 2025
11
Next Earnings Date
H: $-0.09
A: $-0.10
L: $-0.11
H: 1.45M
A: 1.15M
L: 900.00K
Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Seasonals
Price Target
3.79 USD
The 39 analysts offering 1 year price forecasts for LUCD have a max estimate of 7.75 and a min estimate of 2.00.